Hymecromone sodium (4-Methylumbelliferone sodium) is a hyaluronic acid (HA) synthesis inhibitor with an IC50 of 0.4 mM. 4-Methylumbelliferone is a hyaluronic acid (HA) synthesis inhibitor. The activation of HAS2 and the over-production of HA are existed in many metastatic tumor cell lines. Increased synthesis of HA is often associated with increased metastatic potential and invasivity […]

Bupivacaine hydrochloride is a local anesthetic.

Bacteriopheophytin a is a Pigment .

Silk protein hydrolyzates (Silk amino acid; Silk hydrolyzates; silk hydrolysates) is the Hydrolyzed from pure silk fibers, silk amino acids have a lower molecular weight than hydrolyzed silk protein powders as they undergo a greater degree of hydrolysis. Due to their smaller molecular weight they are more penetrating and moisturizing to skin and hair.

ABT-288 is a novel, potent and highly selective histamine-3 receptor antagonist which demonstrated efficacy across several preclinical cognitive domains, and safety in healthy subjects and elderly volunteers. However, it did not demonstrate efficacy in the symptomatic treatment of Alzheimer’s dementia in a randomized, double-blind, placebo- and active-controlled, parallel group design with pre-defined futility criteria to […]

MK-996 is a novel, potent, orally bioactive, highly selective, nonpeptide angiotensin II (AII) receptor antagonist with anti-hypertensive activity. MK-996 prevents the pressor response to intravenous AII in the conscious rat, dog, and rhesus monkey (ED50, mg/kg; oral/intravenous = 0.067/0.014, 0.035/0.017, and 0.1/0.036, respectively). In the anesthetized chimpanzee, MK-996 (1 mg/kg, iv) produces 100% (peak) inhibition […]

Macimorelin (formerly known as UMV-1843; EP-1572; AEZS-130; JMV1843; trade name: Macrilen) is a synthetic small molecule agonist of growth hormone secretagogue receptor that has been approved to diagnose growth hormone deficiency. As a ghrelin agonist, it is orally bioactive and can stimulate the secretion of growth hormone (GH). As of December 2017, it became FDA-approved […]

Naldemedine (formerly known as S-297,995; S297995; trade name: Symproic) is a potent, orally bioavailable peripherally active, and selective μ-opioid receptor antagonist developed by Shionogi and has been approved in 2017 for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Clinical studies have thus far found it to possess statistically significant effectiveness […]

Serlopitant (also known as VPD-737 and MK-0594) is a novel, potent and selective antagonist of Neurokinin-1 (NK-1) receptor which is being evuluated in clinical trials for the treatment of urinary incontinence and overactive bladder, while it was superior to placebo it provided no advantage over existing drugs, and the further development was discontinued. The substance […]

Rislenemdaz (also known as MK-065; CERC-301) is a novel, potent, orally bioavailable and selective antagonist of the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GluN2B) with Ki and IC50 of 8.1 nM and 3.6 nM, respectively. It has the potential for the treatment of Parkinson’s disease. In the preclinical pharmacological and pharmacokinetic study, CERC-301 demonstrated high-binding affinity […]